OncoTherapy Science（4564）株式概要オンコセラピー・サイエンス社は、日本では抗ボディ薬の研究開発、がんのゲノム解析、リキッドバイオプシー、新規免疫療法の開発を行っている。 詳細4564 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析JP市場と比較して、過去 3 か月間の株価の変動が非常に大きい過去1年間で株主の希薄化は大幅に進んだ 意味のある時価総額がありません ( ¥8B )すべてのリスクチェックを見る4564 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueJP¥Current PriceJP¥20.00719.7% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-3b1b2016201920222025202620282031Revenue JP¥828.7mEarnings JP¥154.3mAdvancedSet Fair ValueView all narrativesOncoTherapy Science, Inc. 競合他社Nano HoldingsSymbol: TSE:4571Market cap: JP¥8.7bKidswell BioSymbol: TSE:4584Market cap: JP¥6.6bKohjin BioSymbol: TSE:177AMarket cap: JP¥5.1bReproCELLSymbol: TSE:4978Market cap: JP¥12.4b価格と性能株価の高値、安値、推移の概要OncoTherapy Science過去の株価現在の株価JP¥20.0052週高値JP¥35.0052週安値JP¥18.00ベータ0.261ヶ月の変化0%3ヶ月変化-13.04%1年変化-16.67%3年間の変化-54.55%5年間の変化-82.46%IPOからの変化-98.50%最新ニュースReported Earnings • May 09Full year 2026 earnings released: JP¥2.77 loss per share (vs JP¥3.12 loss in FY 2025)Full year 2026 results: JP¥2.77 loss per share. Revenue: JP¥808.0m (up 7.7% from FY 2025). Net loss: JP¥910.0m (loss widened 12% from FY 2025).お知らせ • May 08OncoTherapy Science, Inc., Annual General Meeting, Jun 23, 2026OncoTherapy Science, Inc., Annual General Meeting, Jun 23, 2026.分析記事 • Apr 23OncoTherapy Science (TSE:4564) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...New Risk • Apr 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.9% average weekly change). Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Minor Risks Revenue is less than US$5m (JP¥784m revenue, or US$4.9m). Market cap is less than US$100m (JP¥11.9b market cap, or US$74.8m).Reported Earnings • Feb 08Third quarter 2026 earnings released: JP¥0.66 loss per share (vs JP¥0.63 loss in 3Q 2025)Third quarter 2026 results: JP¥0.66 loss per share (further deteriorated from JP¥0.63 loss in 3Q 2025). Revenue: JP¥166.0m (down 51% from 3Q 2025). Net loss: JP¥228.0m (loss widened 33% from 3Q 2025). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.New Risk • Feb 08New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: JP¥784m (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.0% average weekly change). Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Minor Risks Revenue is less than US$5m (JP¥784m revenue, or US$5.0m). Market cap is less than US$100m (JP¥7.53b market cap, or US$47.9m).最新情報をもっと見るRecent updatesReported Earnings • May 09Full year 2026 earnings released: JP¥2.77 loss per share (vs JP¥3.12 loss in FY 2025)Full year 2026 results: JP¥2.77 loss per share. Revenue: JP¥808.0m (up 7.7% from FY 2025). Net loss: JP¥910.0m (loss widened 12% from FY 2025).お知らせ • May 08OncoTherapy Science, Inc., Annual General Meeting, Jun 23, 2026OncoTherapy Science, Inc., Annual General Meeting, Jun 23, 2026.分析記事 • Apr 23OncoTherapy Science (TSE:4564) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...New Risk • Apr 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.9% average weekly change). Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Minor Risks Revenue is less than US$5m (JP¥784m revenue, or US$4.9m). Market cap is less than US$100m (JP¥11.9b market cap, or US$74.8m).Reported Earnings • Feb 08Third quarter 2026 earnings released: JP¥0.66 loss per share (vs JP¥0.63 loss in 3Q 2025)Third quarter 2026 results: JP¥0.66 loss per share (further deteriorated from JP¥0.63 loss in 3Q 2025). Revenue: JP¥166.0m (down 51% from 3Q 2025). Net loss: JP¥228.0m (loss widened 33% from 3Q 2025). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.New Risk • Feb 08New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: JP¥784m (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.0% average weekly change). Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Minor Risks Revenue is less than US$5m (JP¥784m revenue, or US$5.0m). Market cap is less than US$100m (JP¥7.53b market cap, or US$47.9m).New Risk • Jan 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 39% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.2% average weekly change). Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Minor Risk Market cap is less than US$100m (JP¥7.91b market cap, or US$49.9m).分析記事 • Jan 08We're Hopeful That OncoTherapy Science (TSE:4564) Will Use Its Cash WiselyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...New Risk • Nov 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 25% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.4% average weekly change). Minor Risks Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (JP¥7.11b market cap, or US$45.3m).Reported Earnings • Nov 09Second quarter 2026 earnings released: JP¥0.78 loss per share (vs JP¥0.91 loss in 2Q 2025)Second quarter 2026 results: JP¥0.78 loss per share (improved from JP¥0.91 loss in 2Q 2025). Revenue: JP¥230.0m (up 84% from 2Q 2025). Net loss: JP¥241.0m (flat on 2Q 2025). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.お知らせ • Nov 07OncoTherapy Science, Inc. to Report Q2, 2026 Results on Nov 07, 2025OncoTherapy Science, Inc. announced that they will report Q2, 2026 results on Nov 07, 2025分析記事 • Sep 24Here's Why We're Not Too Worried About OncoTherapy Science's (TSE:4564) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...Reported Earnings • Aug 10First quarter 2026 earnings released: JP¥1.13 loss per share (vs JP¥1.30 loss in 1Q 2025)First quarter 2026 results: JP¥1.13 loss per share. Revenue: JP¥201.0m (up 101% from 1Q 2025). Net loss: JP¥314.0m (loss widened 4.0% from 1Q 2025).お知らせ • Aug 08OncoTherapy Science, Inc. to Report Q1, 2026 Results on Aug 08, 2025OncoTherapy Science, Inc. announced that they will report Q1, 2026 results on Aug 08, 2025Reported Earnings • Jun 29Full year 2025 earnings released: JP¥3.12 loss per share (vs JP¥6.05 loss in FY 2024)Full year 2025 results: JP¥3.12 loss per share (improved from JP¥6.05 loss in FY 2024). Revenue: JP¥750.0m (up 23% from FY 2024). Net loss: JP¥815.0m (loss narrowed 37% from FY 2024). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.New Risk • Jun 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 15% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.5% average weekly change). Minor Risks Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (JP¥6.62b market cap, or US$45.6m).New Risk • Jun 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.3% average weekly change). Minor Risk Market cap is less than US$100m (JP¥5.79b market cap, or US$40.3m).Reported Earnings • May 11Full year 2025 earnings released: JP¥3.12 loss per share (vs JP¥6.05 loss in FY 2024)Full year 2025 results: JP¥3.12 loss per share (improved from JP¥6.05 loss in FY 2024). Revenue: JP¥750.0m (up 23% from FY 2024). Net loss: JP¥815.0m (loss narrowed 37% from FY 2024). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.お知らせ • May 09+ 1 more updateOncoTherapy Science, Inc., Annual General Meeting, Jun 24, 2025OncoTherapy Science, Inc., Annual General Meeting, Jun 24, 2025.お知らせ • Apr 28OncoTherapy Science, Inc. announced that it has received ¥84.87 million in funding from Long Corridor Asset Management LimitedOn April 28, 2025, OncoTherapy Science, Inc., closed the transaction.お知らせ • Apr 10OncoTherapy Science, Inc. announced that it expects to receive ¥84.87 million in funding from Long Corridor Asset Management LimitedOncoTherapy Science, Inc. announced a private placement to issue 4,000,000 common shares at issue price of ¥19.8 per share for gross proceeds of ¥79,200,000 and 630,000 37th series stock acquisition rights at issue price of ¥9 per stock acquisition right for gross proceeds of ¥5,670,000 on April 10, 2025. The minimum exercise price for the stock acquisition rights is ¥11 and initial exercise price is¥22 yen and the number of potential shares is 63,000,000 shares. The exercise period of stock acquisition rights starts from April 30, 2025 to April 28, 2028. The transaction includes investor participation of Long Corridor Alpha Opportunities Master Fund (LCAO for 3,400,000 shares and 535,500 units and MAP246 Segregated Portfolio (MAP246) for 600,000 shares and 94,500 units. The transaction has been approved by the board of directors of the company. The transaction is expected to close on April 28, 2025.Reported Earnings • Feb 08Third quarter 2025 earnings released: JP¥0.63 loss per share (vs JP¥1.27 loss in 3Q 2024)Third quarter 2025 results: JP¥0.63 loss per share (improved from JP¥1.27 loss in 3Q 2024). Revenue: JP¥338.0m (up 207% from 3Q 2024). Net loss: JP¥172.0m (loss narrowed 38% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.お知らせ • Feb 07OncoTherapy Science, Inc. to Report Q3, 2025 Results on Feb 07, 2025OncoTherapy Science, Inc. announced that they will report Q3, 2025 results on Feb 07, 2025分析記事 • Jan 29We're Keeping An Eye On OncoTherapy Science's (TSE:4564) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Reported Earnings • Nov 10Second quarter 2025 earnings released: JP¥0.91 loss per share (vs JP¥1.44 loss in 2Q 2024)Second quarter 2025 results: JP¥0.91 loss per share (improved from JP¥1.44 loss in 2Q 2024). Revenue: JP¥125.0m (down 40% from 2Q 2024). Net loss: JP¥243.0m (loss narrowed 22% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.お知らせ • Nov 08OncoTherapy Science, Inc. to Report Q2, 2025 Results on Nov 08, 2024OncoTherapy Science, Inc. announced that they will report Q2, 2025 results on Nov 08, 2024分析記事 • Oct 11Is OncoTherapy Science (TSE:4564) In A Good Position To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, although...New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (22% average weekly change). Minor Risks Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (JP¥9.81b market cap, or US$69.7m).New Risk • Aug 11New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥1.2b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.2b free cash flow). Share price has been highly volatile over the past 3 months (31% average weekly change). Minor Risks Shareholders have been diluted in the past year (27% increase in shares outstanding). Revenue is less than US$5m (JP¥562m revenue, or US$3.8m). Market cap is less than US$100m (JP¥12.9b market cap, or US$87.8m).Reported Earnings • Aug 11First quarter 2025 earnings released: JP¥1.30 loss per share (vs JP¥1.99 loss in 1Q 2024)First quarter 2025 results: JP¥1.30 loss per share (improved from JP¥1.99 loss in 1Q 2024). Revenue: JP¥100.0m (down 32% from 1Q 2024). Net loss: JP¥302.0m (loss narrowed 25% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.お知らせ • Aug 08OncoTherapy Science, Inc. to Report Q1, 2025 Results on Aug 09, 2024OncoTherapy Science, Inc. announced that they will report Q1, 2025 results on Aug 09, 2024Reported Earnings • May 13Full year 2024 earnings released: JP¥6.05 loss per share (vs JP¥5.80 loss in FY 2023)Full year 2024 results: JP¥6.05 loss per share (further deteriorated from JP¥5.80 loss in FY 2023). Revenue: JP¥610.0m (down 46% from FY 2023). Net loss: JP¥1.29b (loss widened 15% from FY 2023). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.お知らせ • May 12+ 1 more updateOncoTherapy Science, Inc. to Report Fiscal Year 2024 Results on May 10, 2024OncoTherapy Science, Inc. announced that they will report fiscal year 2024 results on May 10, 2024お知らせ • Apr 05OncoTherapy Science, Inc. announced that it expects to receive ¥3.78 million in funding from Long Corridor Asset Management Limited and another investorOncoTherapy Science, Inc. announced a private placement of 540,000 36th stock acquisition rights at a price of ¥7 per warrant for the gross proceeds of ¥3,780,000 on April 5, 2024. The transaction will include participation from new investor, Long Corridor Asset Management Limited, Long Corridor Alpha Opportunities Master Fund. The warrants will be convertible into common shares at an exercise of ¥19 per share. The transaction has been approved by the shareholders of the company and is expected to close on April 22, 2024.分析記事 • Mar 01We're A Little Worried About OncoTherapy Science's (TSE:4564) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Reported Earnings • Feb 11Third quarter 2024 earnings released: JP¥1.27 loss per share (vs JP¥1.56 loss in 3Q 2023)Third quarter 2024 results: JP¥1.27 loss per share (improved from JP¥1.56 loss in 3Q 2023). Revenue: JP¥110.0m (down 41% from 3Q 2023). Net loss: JP¥277.0m (loss narrowed 7.7% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.お知らせ • Feb 10OncoTherapy Science, Inc. to Report Q3, 2024 Results on Feb 09, 2024OncoTherapy Science, Inc. announced that they will report Q3, 2024 results on Feb 09, 2024Reported Earnings • Nov 12Second quarter 2024 earnings released: JP¥1.44 loss per share (vs JP¥1.74 loss in 2Q 2023)Second quarter 2024 results: JP¥1.44 loss per share (improved from JP¥1.74 loss in 2Q 2023). Revenue: JP¥208.0m (up 61% from 2Q 2023). Net loss: JP¥310.0m (loss narrowed 7.7% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.お知らせ • Nov 10OncoTherapy Science, Inc. to Report Q2, 2024 Results on Nov 10, 2023OncoTherapy Science, Inc. announced that they will report Q2, 2024 results on Nov 10, 2023Reported Earnings • Aug 12First quarter 2024 earnings released: JP¥1.99 loss per share (vs JP¥1.44 loss in 1Q 2023)First quarter 2024 results: JP¥1.99 loss per share (further deteriorated from JP¥1.44 loss in 1Q 2023). Revenue: JP¥148.0m (down 62% from 1Q 2023). Net loss: JP¥400.0m (loss widened 44% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.お知らせ • Aug 10OncoTherapy Science, Inc. to Report Q1, 2024 Results on Aug 10, 2023OncoTherapy Science, Inc. announced that they will report Q1, 2024 results on Aug 10, 2023New Risk • Jun 23New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥798m free cash flow). Share price has been highly volatile over the past 3 months (8.1% average weekly change). Minor Risks Shareholders have been diluted in the past year (7.3% increase in shares outstanding). Market cap is less than US$100m (JP¥8.68b market cap, or US$60.6m).Reported Earnings • May 17Full year 2023 earnings released: JP¥5.80 loss per share (vs JP¥13.71 loss in FY 2022)Full year 2023 results: JP¥5.80 loss per share (improved from JP¥13.71 loss in FY 2022). Revenue: JP¥1.13b (down 1.6% from FY 2022). Net loss: JP¥1.12b (loss narrowed 56% from FY 2022). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.お知らせ • May 12OncoTherapy Science, Inc. to Report Fiscal Year 2023 Results on May 12, 2023OncoTherapy Science, Inc. announced that they will report fiscal year 2023 results on May 12, 2023Board Change • May 10Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent External Director Yoshio Miki was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 12Third quarter 2023 earnings released: JP¥1.56 loss per share (vs JP¥4.73 loss in 3Q 2022)Third quarter 2023 results: JP¥1.56 loss per share (improved from JP¥4.73 loss in 3Q 2022). Revenue: JP¥185.0m (up 95% from 3Q 2022). Net loss: JP¥300.0m (loss narrowed 67% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.お知らせ • Feb 09OncoTherapy Science, Inc. to Report Q3, 2023 Results on Feb 10, 2023OncoTherapy Science, Inc. announced that they will report Q3, 2023 results on Feb 10, 2023Reported Earnings • Nov 06Second quarter 2023 earnings released: JP¥1.74 loss per share (vs JP¥3.72 loss in 2Q 2022)Second quarter 2023 results: JP¥1.74 loss per share (improved from JP¥3.72 loss in 2Q 2022). Revenue: JP¥129.0m (down 12% from 2Q 2022). Net loss: JP¥336.0m (loss narrowed 52% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 07First quarter 2023 earnings released: JP¥1.44 loss per share (vs JP¥3.00 loss in 1Q 2022)First quarter 2023 results: JP¥1.44 loss per share (up from JP¥3.00 loss in 1Q 2022). Revenue: JP¥385.0m (up 314% from 1Q 2022). Net loss: JP¥277.0m (loss narrowed 48% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Reported Earnings • Jun 24Full year 2022 earnings released: JP¥13.71 loss per share (vs JP¥8.85 loss in FY 2021)Full year 2022 results: JP¥13.71 loss per share (down from JP¥8.85 loss in FY 2021). Revenue: JP¥1.15b (up 247% from FY 2021). Net loss: JP¥2.57b (loss widened 65% from FY 2021). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Reported Earnings • May 11Full year 2022 earnings released: JP¥13.71 loss per share (vs JP¥8.85 loss in FY 2021)Full year 2022 results: JP¥13.71 loss per share (down from JP¥8.85 loss in FY 2021). Revenue: JP¥1.15b (up 247% from FY 2021). Net loss: JP¥2.57b (loss widened 65% from FY 2021). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 07Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: JP¥4.73 loss per share (down from JP¥2.42 loss in 3Q 2021). Revenue: JP¥95.0m (up 58% from 3Q 2021). Net loss: JP¥910.0m (loss widened 114% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 07Second quarter 2022 earnings released: JP¥3.72 loss per share (vs JP¥2.48 loss in 2Q 2021)The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2022 results: Revenue: JP¥147.0m (up 149% from 2Q 2021). Net loss: JP¥695.0m (loss widened 59% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 09First quarter 2022 earnings released: JP¥3.00 loss per share (vs JP¥1.80 loss in 1Q 2021)The company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2022 results: Revenue: JP¥93.0m (up 127% from 1Q 2021). Net loss: JP¥534.0m (loss widened 68% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.Reported Earnings • Jun 24Full year 2021 earnings released: JP¥8.85 loss per share (vs JP¥13.73 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: JP¥332.0m (up 5.1% from FY 2020). Net loss: JP¥1.56b (loss narrowed 30% from FY 2020). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.Reported Earnings • May 09Full year 2021 earnings released: JP¥8.85 loss per share (vs JP¥13.73 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: JP¥332.0m (up 5.1% from FY 2020). Net loss: JP¥1.56b (loss narrowed 30% from FY 2020). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 08Third quarter 2021 earnings released: JP¥2.42 loss per share (vs JP¥3.17 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: JP¥60.0m (up 5.3% from 3Q 2020). Net loss: JP¥426.0m (loss narrowed 18% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Dec 07New 90-day low: JP¥124The company is down 2.0% from its price of JP¥126 on 08 September 2020. The Japanese market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 10.0% over the same period.株主還元4564JP BiotechsJP 市場7D5.3%-6.8%2.9%1Y-16.7%-31.6%43.8%株主還元を見る業界別リターン: 4564過去 1 年間で-31.6 % の収益を上げたJP Biotechs業界を上回りました。リターン対市場: 4564は、過去 1 年間で43.8 % のリターンを上げたJP市場を下回りました。価格変動Is 4564's price volatile compared to industry and market?4564 volatility4564 Average Weekly Movement11.8%Biotechs Industry Average Movement7.7%Market Average Movement4.6%10% most volatile stocks in JP Market9.3%10% least volatile stocks in JP Market2.4%安定した株価: 4564の株価は、 JP市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 4564の weekly volatility ( 12% ) は過去 1 年間安定していますが、依然としてJPの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト200147Junichi Shimadawww.oncotherapy.co.jpオンコセラピー・サイエンス株式会社は、日本において、抗体医薬の研究開発、がんのゲノム解析、リキッドバイオプシー、新規免疫療法の開発を行っている。同社の開発パイプラインには、急性骨髄性白血病の治療薬として第I/II相臨床試験中であり、乳がんの治療薬として第I相臨床試験中の母体胚ロイシンジッパーキナーゼ阻害剤を標的とする低分子化合物OTS167、現在非臨床段階にある低分子TOPK阻害剤OTS964などがある。また、がんペプチドワクチンのパイプラインも有しており、食道がんを対象とした第III相臨床試験および膀胱がんを対象とした第II相臨床試験を終了したS-588410、頭頸部がんを対象とした第I/II相臨床試験中のS-488210、固形がんを対象とした第I相臨床試験中のS-588210、胃がんを対象とした第I相臨床試験中のOTSGC-A24などがある。また、滑膜肉腫を対象とした第I相臨床試験中のOTSA101、アルツハイマー病を対象とした第I相臨床試験を終了した抗アミロイドβペプチド抗体からなる抗体医薬を開発している。オンコセラピー・サイエンス社は2001年に設立され、川崎市に本社を置いている。もっと見るOncoTherapy Science, Inc. 基礎のまとめOncoTherapy Science の収益と売上を時価総額と比較するとどうか。4564 基礎統計学時価総額JP¥7.67b収益（TTM）-JP¥910.00m売上高(TTM)JP¥808.00m9.5xP/Sレシオ-8.4xPER（株価収益率4564 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計4564 損益計算書（TTM）収益JP¥808.00m売上原価JP¥1.33b売上総利益-JP¥521.00mその他の費用JP¥389.00m収益-JP¥910.00m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-2.37グロス・マージン-64.48%純利益率-112.62%有利子負債／自己資本比率0%4564 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/17 22:27終値2026/06/17 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋OncoTherapy Science, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Kiyokazu YamazakiIchiyoshi Research Institute Inc.Toshiyuki IwataMizuho Securities Co., Ltd.
Reported Earnings • May 09Full year 2026 earnings released: JP¥2.77 loss per share (vs JP¥3.12 loss in FY 2025)Full year 2026 results: JP¥2.77 loss per share. Revenue: JP¥808.0m (up 7.7% from FY 2025). Net loss: JP¥910.0m (loss widened 12% from FY 2025).
お知らせ • May 08OncoTherapy Science, Inc., Annual General Meeting, Jun 23, 2026OncoTherapy Science, Inc., Annual General Meeting, Jun 23, 2026.
分析記事 • Apr 23OncoTherapy Science (TSE:4564) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
New Risk • Apr 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.9% average weekly change). Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Minor Risks Revenue is less than US$5m (JP¥784m revenue, or US$4.9m). Market cap is less than US$100m (JP¥11.9b market cap, or US$74.8m).
Reported Earnings • Feb 08Third quarter 2026 earnings released: JP¥0.66 loss per share (vs JP¥0.63 loss in 3Q 2025)Third quarter 2026 results: JP¥0.66 loss per share (further deteriorated from JP¥0.63 loss in 3Q 2025). Revenue: JP¥166.0m (down 51% from 3Q 2025). Net loss: JP¥228.0m (loss widened 33% from 3Q 2025). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.
New Risk • Feb 08New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: JP¥784m (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.0% average weekly change). Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Minor Risks Revenue is less than US$5m (JP¥784m revenue, or US$5.0m). Market cap is less than US$100m (JP¥7.53b market cap, or US$47.9m).
Reported Earnings • May 09Full year 2026 earnings released: JP¥2.77 loss per share (vs JP¥3.12 loss in FY 2025)Full year 2026 results: JP¥2.77 loss per share. Revenue: JP¥808.0m (up 7.7% from FY 2025). Net loss: JP¥910.0m (loss widened 12% from FY 2025).
お知らせ • May 08OncoTherapy Science, Inc., Annual General Meeting, Jun 23, 2026OncoTherapy Science, Inc., Annual General Meeting, Jun 23, 2026.
分析記事 • Apr 23OncoTherapy Science (TSE:4564) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
New Risk • Apr 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.9% average weekly change). Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Minor Risks Revenue is less than US$5m (JP¥784m revenue, or US$4.9m). Market cap is less than US$100m (JP¥11.9b market cap, or US$74.8m).
Reported Earnings • Feb 08Third quarter 2026 earnings released: JP¥0.66 loss per share (vs JP¥0.63 loss in 3Q 2025)Third quarter 2026 results: JP¥0.66 loss per share (further deteriorated from JP¥0.63 loss in 3Q 2025). Revenue: JP¥166.0m (down 51% from 3Q 2025). Net loss: JP¥228.0m (loss widened 33% from 3Q 2025). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.
New Risk • Feb 08New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: JP¥784m (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.0% average weekly change). Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Minor Risks Revenue is less than US$5m (JP¥784m revenue, or US$5.0m). Market cap is less than US$100m (JP¥7.53b market cap, or US$47.9m).
New Risk • Jan 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 39% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.2% average weekly change). Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Minor Risk Market cap is less than US$100m (JP¥7.91b market cap, or US$49.9m).
分析記事 • Jan 08We're Hopeful That OncoTherapy Science (TSE:4564) Will Use Its Cash WiselyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
New Risk • Nov 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 25% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.4% average weekly change). Minor Risks Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (JP¥7.11b market cap, or US$45.3m).
Reported Earnings • Nov 09Second quarter 2026 earnings released: JP¥0.78 loss per share (vs JP¥0.91 loss in 2Q 2025)Second quarter 2026 results: JP¥0.78 loss per share (improved from JP¥0.91 loss in 2Q 2025). Revenue: JP¥230.0m (up 84% from 2Q 2025). Net loss: JP¥241.0m (flat on 2Q 2025). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
お知らせ • Nov 07OncoTherapy Science, Inc. to Report Q2, 2026 Results on Nov 07, 2025OncoTherapy Science, Inc. announced that they will report Q2, 2026 results on Nov 07, 2025
分析記事 • Sep 24Here's Why We're Not Too Worried About OncoTherapy Science's (TSE:4564) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Reported Earnings • Aug 10First quarter 2026 earnings released: JP¥1.13 loss per share (vs JP¥1.30 loss in 1Q 2025)First quarter 2026 results: JP¥1.13 loss per share. Revenue: JP¥201.0m (up 101% from 1Q 2025). Net loss: JP¥314.0m (loss widened 4.0% from 1Q 2025).
お知らせ • Aug 08OncoTherapy Science, Inc. to Report Q1, 2026 Results on Aug 08, 2025OncoTherapy Science, Inc. announced that they will report Q1, 2026 results on Aug 08, 2025
Reported Earnings • Jun 29Full year 2025 earnings released: JP¥3.12 loss per share (vs JP¥6.05 loss in FY 2024)Full year 2025 results: JP¥3.12 loss per share (improved from JP¥6.05 loss in FY 2024). Revenue: JP¥750.0m (up 23% from FY 2024). Net loss: JP¥815.0m (loss narrowed 37% from FY 2024). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
New Risk • Jun 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 15% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.5% average weekly change). Minor Risks Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (JP¥6.62b market cap, or US$45.6m).
New Risk • Jun 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.3% average weekly change). Minor Risk Market cap is less than US$100m (JP¥5.79b market cap, or US$40.3m).
Reported Earnings • May 11Full year 2025 earnings released: JP¥3.12 loss per share (vs JP¥6.05 loss in FY 2024)Full year 2025 results: JP¥3.12 loss per share (improved from JP¥6.05 loss in FY 2024). Revenue: JP¥750.0m (up 23% from FY 2024). Net loss: JP¥815.0m (loss narrowed 37% from FY 2024). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.
お知らせ • May 09+ 1 more updateOncoTherapy Science, Inc., Annual General Meeting, Jun 24, 2025OncoTherapy Science, Inc., Annual General Meeting, Jun 24, 2025.
お知らせ • Apr 28OncoTherapy Science, Inc. announced that it has received ¥84.87 million in funding from Long Corridor Asset Management LimitedOn April 28, 2025, OncoTherapy Science, Inc., closed the transaction.
お知らせ • Apr 10OncoTherapy Science, Inc. announced that it expects to receive ¥84.87 million in funding from Long Corridor Asset Management LimitedOncoTherapy Science, Inc. announced a private placement to issue 4,000,000 common shares at issue price of ¥19.8 per share for gross proceeds of ¥79,200,000 and 630,000 37th series stock acquisition rights at issue price of ¥9 per stock acquisition right for gross proceeds of ¥5,670,000 on April 10, 2025. The minimum exercise price for the stock acquisition rights is ¥11 and initial exercise price is¥22 yen and the number of potential shares is 63,000,000 shares. The exercise period of stock acquisition rights starts from April 30, 2025 to April 28, 2028. The transaction includes investor participation of Long Corridor Alpha Opportunities Master Fund (LCAO for 3,400,000 shares and 535,500 units and MAP246 Segregated Portfolio (MAP246) for 600,000 shares and 94,500 units. The transaction has been approved by the board of directors of the company. The transaction is expected to close on April 28, 2025.
Reported Earnings • Feb 08Third quarter 2025 earnings released: JP¥0.63 loss per share (vs JP¥1.27 loss in 3Q 2024)Third quarter 2025 results: JP¥0.63 loss per share (improved from JP¥1.27 loss in 3Q 2024). Revenue: JP¥338.0m (up 207% from 3Q 2024). Net loss: JP¥172.0m (loss narrowed 38% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
お知らせ • Feb 07OncoTherapy Science, Inc. to Report Q3, 2025 Results on Feb 07, 2025OncoTherapy Science, Inc. announced that they will report Q3, 2025 results on Feb 07, 2025
分析記事 • Jan 29We're Keeping An Eye On OncoTherapy Science's (TSE:4564) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Reported Earnings • Nov 10Second quarter 2025 earnings released: JP¥0.91 loss per share (vs JP¥1.44 loss in 2Q 2024)Second quarter 2025 results: JP¥0.91 loss per share (improved from JP¥1.44 loss in 2Q 2024). Revenue: JP¥125.0m (down 40% from 2Q 2024). Net loss: JP¥243.0m (loss narrowed 22% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
お知らせ • Nov 08OncoTherapy Science, Inc. to Report Q2, 2025 Results on Nov 08, 2024OncoTherapy Science, Inc. announced that they will report Q2, 2025 results on Nov 08, 2024
分析記事 • Oct 11Is OncoTherapy Science (TSE:4564) In A Good Position To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, although...
New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (22% average weekly change). Minor Risks Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (JP¥9.81b market cap, or US$69.7m).
New Risk • Aug 11New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥1.2b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.2b free cash flow). Share price has been highly volatile over the past 3 months (31% average weekly change). Minor Risks Shareholders have been diluted in the past year (27% increase in shares outstanding). Revenue is less than US$5m (JP¥562m revenue, or US$3.8m). Market cap is less than US$100m (JP¥12.9b market cap, or US$87.8m).
Reported Earnings • Aug 11First quarter 2025 earnings released: JP¥1.30 loss per share (vs JP¥1.99 loss in 1Q 2024)First quarter 2025 results: JP¥1.30 loss per share (improved from JP¥1.99 loss in 1Q 2024). Revenue: JP¥100.0m (down 32% from 1Q 2024). Net loss: JP¥302.0m (loss narrowed 25% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
お知らせ • Aug 08OncoTherapy Science, Inc. to Report Q1, 2025 Results on Aug 09, 2024OncoTherapy Science, Inc. announced that they will report Q1, 2025 results on Aug 09, 2024
Reported Earnings • May 13Full year 2024 earnings released: JP¥6.05 loss per share (vs JP¥5.80 loss in FY 2023)Full year 2024 results: JP¥6.05 loss per share (further deteriorated from JP¥5.80 loss in FY 2023). Revenue: JP¥610.0m (down 46% from FY 2023). Net loss: JP¥1.29b (loss widened 15% from FY 2023). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.
お知らせ • May 12+ 1 more updateOncoTherapy Science, Inc. to Report Fiscal Year 2024 Results on May 10, 2024OncoTherapy Science, Inc. announced that they will report fiscal year 2024 results on May 10, 2024
お知らせ • Apr 05OncoTherapy Science, Inc. announced that it expects to receive ¥3.78 million in funding from Long Corridor Asset Management Limited and another investorOncoTherapy Science, Inc. announced a private placement of 540,000 36th stock acquisition rights at a price of ¥7 per warrant for the gross proceeds of ¥3,780,000 on April 5, 2024. The transaction will include participation from new investor, Long Corridor Asset Management Limited, Long Corridor Alpha Opportunities Master Fund. The warrants will be convertible into common shares at an exercise of ¥19 per share. The transaction has been approved by the shareholders of the company and is expected to close on April 22, 2024.
分析記事 • Mar 01We're A Little Worried About OncoTherapy Science's (TSE:4564) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Reported Earnings • Feb 11Third quarter 2024 earnings released: JP¥1.27 loss per share (vs JP¥1.56 loss in 3Q 2023)Third quarter 2024 results: JP¥1.27 loss per share (improved from JP¥1.56 loss in 3Q 2023). Revenue: JP¥110.0m (down 41% from 3Q 2023). Net loss: JP¥277.0m (loss narrowed 7.7% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.
お知らせ • Feb 10OncoTherapy Science, Inc. to Report Q3, 2024 Results on Feb 09, 2024OncoTherapy Science, Inc. announced that they will report Q3, 2024 results on Feb 09, 2024
Reported Earnings • Nov 12Second quarter 2024 earnings released: JP¥1.44 loss per share (vs JP¥1.74 loss in 2Q 2023)Second quarter 2024 results: JP¥1.44 loss per share (improved from JP¥1.74 loss in 2Q 2023). Revenue: JP¥208.0m (up 61% from 2Q 2023). Net loss: JP¥310.0m (loss narrowed 7.7% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.
お知らせ • Nov 10OncoTherapy Science, Inc. to Report Q2, 2024 Results on Nov 10, 2023OncoTherapy Science, Inc. announced that they will report Q2, 2024 results on Nov 10, 2023
Reported Earnings • Aug 12First quarter 2024 earnings released: JP¥1.99 loss per share (vs JP¥1.44 loss in 1Q 2023)First quarter 2024 results: JP¥1.99 loss per share (further deteriorated from JP¥1.44 loss in 1Q 2023). Revenue: JP¥148.0m (down 62% from 1Q 2023). Net loss: JP¥400.0m (loss widened 44% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
お知らせ • Aug 10OncoTherapy Science, Inc. to Report Q1, 2024 Results on Aug 10, 2023OncoTherapy Science, Inc. announced that they will report Q1, 2024 results on Aug 10, 2023
New Risk • Jun 23New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥798m free cash flow). Share price has been highly volatile over the past 3 months (8.1% average weekly change). Minor Risks Shareholders have been diluted in the past year (7.3% increase in shares outstanding). Market cap is less than US$100m (JP¥8.68b market cap, or US$60.6m).
Reported Earnings • May 17Full year 2023 earnings released: JP¥5.80 loss per share (vs JP¥13.71 loss in FY 2022)Full year 2023 results: JP¥5.80 loss per share (improved from JP¥13.71 loss in FY 2022). Revenue: JP¥1.13b (down 1.6% from FY 2022). Net loss: JP¥1.12b (loss narrowed 56% from FY 2022). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.
お知らせ • May 12OncoTherapy Science, Inc. to Report Fiscal Year 2023 Results on May 12, 2023OncoTherapy Science, Inc. announced that they will report fiscal year 2023 results on May 12, 2023
Board Change • May 10Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent External Director Yoshio Miki was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 12Third quarter 2023 earnings released: JP¥1.56 loss per share (vs JP¥4.73 loss in 3Q 2022)Third quarter 2023 results: JP¥1.56 loss per share (improved from JP¥4.73 loss in 3Q 2022). Revenue: JP¥185.0m (up 95% from 3Q 2022). Net loss: JP¥300.0m (loss narrowed 67% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
お知らせ • Feb 09OncoTherapy Science, Inc. to Report Q3, 2023 Results on Feb 10, 2023OncoTherapy Science, Inc. announced that they will report Q3, 2023 results on Feb 10, 2023
Reported Earnings • Nov 06Second quarter 2023 earnings released: JP¥1.74 loss per share (vs JP¥3.72 loss in 2Q 2022)Second quarter 2023 results: JP¥1.74 loss per share (improved from JP¥3.72 loss in 2Q 2022). Revenue: JP¥129.0m (down 12% from 2Q 2022). Net loss: JP¥336.0m (loss narrowed 52% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 07First quarter 2023 earnings released: JP¥1.44 loss per share (vs JP¥3.00 loss in 1Q 2022)First quarter 2023 results: JP¥1.44 loss per share (up from JP¥3.00 loss in 1Q 2022). Revenue: JP¥385.0m (up 314% from 1Q 2022). Net loss: JP¥277.0m (loss narrowed 48% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Reported Earnings • Jun 24Full year 2022 earnings released: JP¥13.71 loss per share (vs JP¥8.85 loss in FY 2021)Full year 2022 results: JP¥13.71 loss per share (down from JP¥8.85 loss in FY 2021). Revenue: JP¥1.15b (up 247% from FY 2021). Net loss: JP¥2.57b (loss widened 65% from FY 2021). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Reported Earnings • May 11Full year 2022 earnings released: JP¥13.71 loss per share (vs JP¥8.85 loss in FY 2021)Full year 2022 results: JP¥13.71 loss per share (down from JP¥8.85 loss in FY 2021). Revenue: JP¥1.15b (up 247% from FY 2021). Net loss: JP¥2.57b (loss widened 65% from FY 2021). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 07Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: JP¥4.73 loss per share (down from JP¥2.42 loss in 3Q 2021). Revenue: JP¥95.0m (up 58% from 3Q 2021). Net loss: JP¥910.0m (loss widened 114% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 07Second quarter 2022 earnings released: JP¥3.72 loss per share (vs JP¥2.48 loss in 2Q 2021)The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2022 results: Revenue: JP¥147.0m (up 149% from 2Q 2021). Net loss: JP¥695.0m (loss widened 59% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 09First quarter 2022 earnings released: JP¥3.00 loss per share (vs JP¥1.80 loss in 1Q 2021)The company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2022 results: Revenue: JP¥93.0m (up 127% from 1Q 2021). Net loss: JP¥534.0m (loss widened 68% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
Reported Earnings • Jun 24Full year 2021 earnings released: JP¥8.85 loss per share (vs JP¥13.73 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: JP¥332.0m (up 5.1% from FY 2020). Net loss: JP¥1.56b (loss narrowed 30% from FY 2020). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
Reported Earnings • May 09Full year 2021 earnings released: JP¥8.85 loss per share (vs JP¥13.73 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: JP¥332.0m (up 5.1% from FY 2020). Net loss: JP¥1.56b (loss narrowed 30% from FY 2020). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 08Third quarter 2021 earnings released: JP¥2.42 loss per share (vs JP¥3.17 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: JP¥60.0m (up 5.3% from 3Q 2020). Net loss: JP¥426.0m (loss narrowed 18% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Dec 07New 90-day low: JP¥124The company is down 2.0% from its price of JP¥126 on 08 September 2020. The Japanese market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 10.0% over the same period.
